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BACKGROUND: The relationship between the diagnostic interval and mortality from colorectal cancer (CRC) is unclear. This association
was examined by taking account of important confounding factors at the time of first presentation of symptoms in primary care.
METHODS: A total of 268 patients with CRC were included in a prospective, population-based study in a Danish county. The diagnostic
interval was defined as the time from first presentation of symptoms until diagnosis. We analysed patients separately according to the
general practitioner’s interpretation of symptoms. Logistic regression was used to estimate 3-year mortality odds ratios as a function
of the diagnostic interval using restricted cubic splines and adjusting for tumour site, comorbidity, age, and sex.
RESULTS: In patients presenting with symptoms suggestive of cancer or any other serious illness, the risk of dying within 3 years
decreased with diagnostic intervals up to 5 weeks and then increased (P¼ 0.002). In patients presenting with vague symptoms,
the association was reverse, although not statistically significant.
CONCLUSION: Detecting cancer in primary care is two sided: aimed at expediting ill patients while preventing healthy people from
going to hospital. This likely explains the counterintuitive findings; but it does not explain the increasing mortality with longer
diagnostic intervals. Thus, this study provides evidence for the hypothesis that the length of the diagnostic interval affects mortality in
CRC patients.
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Studies have shown large variations in the diagnostic intervals
(the time from the first presentation of symptoms in primary care
until diagnosis) for colorectal cancer (CRC) patients, with some
patients experiencing intervals of months (Barrett et al, 2006;
Korsgaard et al, 2006; Hansen et al, 2008; Terhaar et al, 2010).
Although early diagnosis of cancer is generally deemed desirable,
some clinicians and researchers are sceptic about the benefits of
expediting diagnosis for CRC patients (Irvin and Greaney, 1977;
Bako et al, 1988; Rupassara et al, 2006). The reasoning is
that diagnostic intervals, measured in weeks to months, may
be negligible by comparison with the time required for the
development of the tumour, measured in years (Polissar et al,
1981; Pescatori et al, 1982; Auvinen, 1992; Iversen et al, 2009;
Terhaar et al, 2010).
Studies have shown an important, but modest, reduction in CRC
mortality by screening, indicating that time to diagnosis may
matter (Hewitson et al, 2007; Atkin et al, 2010). However, the
majority of CRC patients are diagnosed after presenting with
symptoms, and no randomised trials have examined the benefits
of expediting diagnosis in symptomatic patients (Mitchell et al,
2008). Most of the published literature report data, inevitably, from
observational studies. A recent review indicated a lack of
association between the diagnostic interval and mortality in
CRC patients, but the authors emphasised that future studies
should focus on adjusting for confounding factors, as many of the
included studies had counterintuitive results, showing that
patients with short diagnostic intervals had higher mortality than
patients with long diagnostic intervals (Ramos et al, 2007). Such
findings are usually referred to as the ‘waiting time paradox’ and
have also been reported for other types of cancer (Neal, 2009).
The aim of this study was to analyse the association between the
diagnostic interval and mortality after diagnosis of CRC, while
taking account of the interpretation of symptoms by the general
practitioner (GP) and controlling for confounding factors at first
presentation.
MATERIALS AND METHODS
We conducted a cohort study with overall 3-year mortality as the
primary outcome and the diagnostic interval as the exposure
variable.
Setting
The cohort resided in the former Aarhus County, Denmark, which
has 640 000 inhabitants and B400 new CRC cases per year
(NORDCAN, 2009). Denmark’s publicly funded health-care system
provides free access to general practice and hospital care. More
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than 98% of Danish citizens are registered with a GP whom they
have to consult for medical advice. The GP acts as a gatekeeper to
the rest of the health-care system, carrying out initial diagnostic
investigations and referring patients to hospitals or outpatient
clinics when necessary. Danish GPs are legally bound to keep
detailed medical records of their patients (Christiansen, 2002).
Study population
Our study included all newly diagnosed CRC patients over the age
of 17 during 1 year (1 September 2004 to 31 August 2005).
Subsequently, the study population was restricted to the 89.8% of
patients who had attended general practice before the cancer
diagnosis (see flowchart, Figure 1).
Identification of patients and GPs
Register data for this study were linked by means of the civil
registry number, a unique personal identifier assigned to all
Danish citizens at birth. Patients were identified from the County
Hospital Discharge Registry, a population-based medical database
that records dates of all inpatient and outpatient visits and
discharge diagnoses classified according to the International
Classification of Diseases (ICD-10). We defined incident CRC
patients as patients registered with a first-time discharge diagnosis
of colon cancer (C18 and C19) or rectal cancer (C20) during the
study period; and with no previous diagnosis of colon cancer,
rectal cancer, or malignant neoplasm of ill-defined, secondary, and
unspecified sites (C76-80).
In 2009, we verified all diagnoses by comparing the data with the
Danish Cancer Registry, which records all incident cancer cases in
Denmark and holds key information from the Danish National
Pathology Registry. To identify the patients’ GPs, the data were
linked to the County Health Service Registry (Sørensen, 2009).
Data collection
A questionnaire was sent to each patient’s GP. In practices with
more than one GP, we asked the GP most familiar with the patient
to complete the questionnaire. The GPs received compensation for
their participation (DKK 240 equivalent to EUR 32). Nonrespon-
ders received a reminder after 3 weeks. The GPs were asked to
confirm the diagnosis and provide a detailed description of the
patient’s diagnostic pathway on the basis of the electronic medical
record and discharge letters from hospitals and specialists
(e.g., dates of reported symptoms, encounters, tests, referrals,
and involvement of other providers). GP involvement was defined
on the basis of the question: ‘Were you/your general practice
involved in diagnosing the cancer?’ (yes/no). The questionnaire
also requested information about the symptoms presented by the
patients at the first consultation and about the GP’s interpretation
of those symptoms, that is, as either alarm symptoms suggestive of
cancer, symptoms suggestive of any serious illness, or vague
symptoms not directly suggestive of cancer or other serious illness.
This allowed us to distinguish between patients presenting with
either ‘alarm or any serious symptoms’ or ‘vague symptoms’. The
GP’s symptom interpretation was subjective, that is, not based
on a prespecified list of alarm symptoms. The data collection
has been described in further detail elsewhere (Hansen, 2008;
Hansen et al, 2008).
Data on covariates
We obtained information on age and sex from the civil registry
number. The patients’ complete hospital discharge history,
10 years before the date of first presentation of symptoms to the
GP, was used to compute a Charlson Comorbidity Index score
(Charlson et al, 1987). We grouped levels of comorbidity into ‘no
comorbidity’ (patients with no recorded disease), ‘patients with
moderate comorbidity’ (index score of 1 and 2), and ‘patients with
high comorbidity’ (index score ofX3). To describe data in further
detail, we obtained information from the Danish National Registry
of Patients on emergency admission (yes/no) and from the Danish
Cancer Registry on previous cancers in other sites (yes/no) and
tumour staging classified according to the TNM staging system.
We re-grouped the staging information using the following
principle: stage I (T1-2/N0/M0), II (T3-4/ N0/M0), III (T1-4/
N1-2/M0), IV (T1-4/N0-2/M1), and unknown.
Defining time and mortality
From the Danish Civil Registration System we retrieved informa-
tion on migration and death. The study outcome was death. All
patients were followed for at least 3 years after diagnosis. When
comparing mortality in patients with participating and nonparti-
cipating GPs, the date of the first-time discharge diagnosis of
cancer in the County Hospital Discharge Registry was taken to be
the date of diagnosis.
Statistical analyses
We stratified analyses according to the interpretation of symptoms
by the GP (alarm or any serious symptoms vs vague symptoms), as
we expected the diagnostic pathways to be very different for these
two groups of patients. We initially stratified data into colon and
rectal cancer, as suggested by Ramos et al (2007), but, as the effect
was constant across tumour site, data were pooled to enhance
statistical precision.
The diagnostic interval was grouped into ‘short’ 0 –4 weeks (0–
28 days), ‘medium’ 5–11 weeks (29– 77 days), and ‘long’ X12
IDENTIFIED patients with a first-time discharge
diagnosis of CRC in the County Hospital
Discharge Registry: 393
EXCLUDED
prevalent CRC
patients accord.
to the Danish
Cancer Registry:
30 (7.6%)
STUDY BASE incident CRC patients: 363
EXCLUDED
GP was not
involved in
diagnosing the
cancer: 37
LOST
patients with
non-participating
GP: 58 (16.0%)
STUDY SUBJECTS incident cancer patients
attending primary care before diagnosis: 268
Figure 1 Flowchart showing identification of incident colorectal cancer
(CRC) patients in Aarhus County, Denmark, 2004–2005, for whom
general practice was involved in diagnosing the cancer. The last criterion
could not be determined for patients with nonparticipating GPs.
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weeks (78þ days) roughly based on the 25th and 75th percentiles
and in accordance with the waiting time guarantee of 4 weeks
endorsed by the Danish Government (Olesen et al, 2009).
To estimate the odds ratio (OR) of experiencing long vs short
and medium diagnostic intervals for patients presenting with
vague symptoms vs patients presenting with alarm or any serious
symptoms, we used logistic regression and adjusted for tumour
site (colon/rectal), Charlson Comorbidity Index (0/1–2/X3), age
(18– 59/60– 74/X75), and sex.
Patients who died on the date of diagnosis were included in the
analyses. The survival function up till 3 years after diagnosis was
plotted for each of the three groups of diagnostic interval. We used
logistic regression to estimate 1-year and 3-year mortality OR as a
function of the diagnostic interval adjusted for tumour site,
Charlson Comorbidity Index, age, and sex. We modelled the data
in two ways: first, we calculated the adjusted OR for short or long
vs medium diagnostic intervals.
Second, we treated the diagnostic interval as a continuous variable
using restricted cubic splines in order to make efficient use of within-
category information (Greenland, 1995). We chose an a priori
reference point of 4 weeks (28 days) and used four knots.
To address the possibility that emergency admission was a
confounder and not an intermediate step in the diagnostic pathway,
we additionally adjusted for emergency admission and repeated the
analyses after excluding patients with emergency admissions.
We calculated 95% confidence intervals (95% CIs) for all
estimates and tested each model against a model with no
diagnostic interval term using the Wald test. A two-sided P-value
of p0.05 was defined as statistically significant.
RESULTS
We identified 363 incident CRC patients over the age of 17 years.
In 58 (16.0%) of the cases, the GPs did not participate or complete
the questionnaire (Figure 1). We found no discrepancies between
patients with participating GPs and nonparticipating GPs with
respect to 1-year and 3-year mortality after discharge, age, gender,
comorbidity, tumour stage, previous cancer, or emergency
admission (Table 1).
Out of the 305 incident CRC patients with participating GPs, we
excluded 37 (12.9%) for whom the GP was not involved in
diagnosing the cancer (Figure 1). Compared with the 268 patients
with GP involvement, patients with uninvolved GPs were more
likely to be admitted to hospital as an emergency (Table 1).
The odds of experiencing long vs short diagnostic intervals
(adjusted for comorbidity, age, and sex) were 3.99-fold (95% CI:
2.10, 7.56) higher for the 67 patients presenting with vague
symptoms than for the 201 patients presenting with alarm
symptoms or any serious symptoms. Patients presenting with
vague symptoms had lower levels of comorbidity and were less
likely to present with blood in stools than patients with clear
symptoms (Table 2).
Diagnostic interval and mortality
Overall, 63 (23.5%) CRC patients died within 1 year, and 113
(42.2%) within 3 years of diagnosis (Figure 2).
In patients presenting with alarm symptoms or any serious
symptoms, the adjusted 3-year mortality OR was 2.56 (95% CI:
1.29, 5.05) for short and 2.04 (95% CI: 0.87, 4.77) for long
compared with medium diagnostic intervals (Table 3). The cubic
splines regression analysis (Figure 3) revealed that the risk of
dying within 3 years began to increase after 5 weeks of diagnostic
interval (P¼ 0.002).
In patients presenting with vague symptoms, the adjusted 3-year
mortality OR was 0.71 (95% CI: 0.32, 2.91) for long compared with
medium diagnostic intervals. As only 10 patients had short
diagnostic intervals, comparison with this group was not justified.
The cubic splines regression analysis (Figure 3) revealed a reverse
effect with increasing risk of dying from day 1 and up to B12
weeks, but the association was not statistically significant
(P¼ 0.205).
When analysing 1-year mortality (Table 3), adjusting for
emergency admission or excluding patients with emergency
admissions, we found similar trends and no major changes in
estimates (data not shown).
DISCUSSION
In this population-based cohort study of 268 incident CRC patients
attending primary care before diagnosis, mortality decreased with
diagnostic intervals up to B5 weeks, after which mortality
increased. The counterintuitive finding of short waiting time being
Table 1 Cumulative mortality and clinical features for the study base of
363 of incident colorectal cancer patients
Participating GP
Involved
GP
Uninvolved
GP
Nonparti-
cipating
GP
Total
study
base
N, patients (%) 268 (73.8) 37 (10.2) 58 (16.0) 363 (100)
1-year mortality
after discharge
66 (24.6) 13 (35.1) 21 (36.2) 100 (27.5)
3-year mortality
after discharge
115 (42.9) 20 (54.1) 27 (46.6) 162 (44.6)
Tumour site
Colon 183 (68.3) 30 (81.1) 41 (70.7) 254 (70.0)
Rectal 85 (31.7) 7 (18.9) 17 (29.3) 109 (30.0)
Age at discharge
Median years (IQI) 70 (62–80) 74 (67–80) 72 (62–80) 72 (63–80)
18–59 years 56 (20.9) 5 (13.5) 12 (22.4) 73 (20.1)
60–74 years 104 (38.8) 15 (40.5) 21 (34.5) 140 (38.6)
X75 years 108 (40.3) 17 (45.9) 25 (43.1) 150 (41.3)
Gender
Female 132 (49.3) 16 (43.2) 29 (50.0) 177 (48.8)
Male 136 (50.7) 21 (56.8) 29 (50.0) 186 (51.2)
Charlson Comorbidity Index at discharge
Low (0) 139 (51.9) 17 (45.9) 31 (53.4) 187 (51.5)
Moderate (1–2) 97 (36.2) 13 (35.1) 18 (31.0) 128 (35.3)
High (X3) 32 (11.9) 7 (18.9) 9 (15.5) 48 (13.2)
Previous cancer
Yes 40 (14.9) 10 (27.0) 13 (22.4) 63 (17.4)
No 228 (85.1) 27 (73.0) 45 (77.6) 300 (82.6)
Tumour stage (TNM)
I 25 (9.3) 2 (5.4) 6 (10.3) 33 (9.1)
II 94 (35.1) 10 (27.0) 22 (37.9) 126 (34.7)
III 71 (26.5) 11 (29.7) 11 (19.0) 93 (25.6)
IV 56 (20.9) 6 (16.2) 13 (22.4) 75 (20.7)
Unknown 22 (8.2) 8 (21.6) 6 (10.3) 36 (9.9)
Emergency admission
Yes 65 (24.3) 21 (56.8)a 17 (29.3) 103 (28.4)
No 203 (75.7) 16 (43.2) 41 (70.7) 260 (71.6)
Abbreviations: GP¼ general practitioner; IQI¼ interquartile interval; TNM¼ tumour,
node, metastasis. aPp0.05 using a log-rank test for equality of survivor functions and a
w2 test for difference between groups comparing (1) patients with participating and
nonparticipating GPs and (2) patients with involved and uninvolved participating GPs.
No statistically significant differences were found between the former groups.
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associated with high mortality only applied to patients presenting
with alarm symptoms or any serious symptoms. In the quarter of
patients presenting with vague symptoms, the association was
reverse although not statistically significant.
Strengths of the study
The strengths of the study lie in the population-based design made
possible by a uniformly organised health-care system and vali-
dation using histological confirmation of diagnoses and complete
follow-up, all of which reduced selection and information bias.
The high response rate among GPs (84.0%) also reduced the
potential for selection bias. By excluding patients in whose
diagnosis the GPs had not been involved, we ensured a more
accurate measure of the exposure (the diagnostic interval) and a
Table 2 Characteristics of 268 incident colorectal cancer patients with
GP involvement presenting with either: (a) alarm symptoms of cancer or
symptoms related to any serious illness or with (b) vague or ill-defined
symptoms not directly related to cancer or any other serious illness
(a) Alarm or
any serious
symptoms
(b) Vague
symptoms Total
Number of subjects (%) 201 (75) 67 (25) 268 (100)
Diagnostic interval (time from first presentation of symptoms in primary
care to diagnosis)*
Median days (IQI) 37 (21–68) 74 (40–152) 40 (23–71)
Age at first presentation of symptoms in primary care
Median years (IQI) 71 (62–79) 70 (62–81) 71 (62–80)
Age groups n (%) n (%) n (%)
18–59 years 41 (20) 15 (22) 56 (21)
60–74 years 76 (38) 29 (43) 105 (39)
X75 years 84 (42) 23 (34) 107 (40)
Sex
Female 95 (47) 37 (55) 132 (49)
Male 106 (53) 30 (45) 136 (51)
Comorbidity at first presentation of symptoms in primary care**
Low (0) 115 (57) 52 (78) 167 (62)
Moderate (1–2) 67 (33) 12 (18) 79 (29)
High (X3) 19 (9) 3 (4) 22 (8)
Previous cancer
Yes 30 (15) 10 (15) 40 (15)
No 171 (85) 57 (85) 228 (85)
Tumour stage (TNM)
I 20 (10) 5 (7) 25 (9)
II 73 (36) 21 (31) 94 (35)
III 54 (27) 17 (25) 71 (26)
IV 37 (18) 19 (28) 56 (21)
Unknown 17 (8) 5 (7) 22 (8)
Emergency admission
Yes 43 (21) 22 (33) 65 (24)
No 158 (79) 45 (67) 203 (76)
Patient presented with change in bowel habits
Yes 101 (50) 25 (37) 126 (47)
No 101 (50) 42 (63) 143 (53)
Patient presented with blood in stools**
Yes 94 (47) 7 (10) 101 (38)
No 107 (53) 60 (90) 167 (62)
Abbreviations: GP¼ general practitioner; IQI¼ interquartile interval; TNM¼ tumour,
node, metastasis. *Pp0.05 using independent sample t-test for difference in median
diagnostic intervals (log transformed distributions) comparing alarm or any serious
with vague. **Pp0.05 using w2 test for difference between groups (alarm or any
serious vs vague symptoms).
Alarm or any serious symptoms
n (deaths)/N = 80/201
Vague symptoms
n (deaths)/N = 33/67
Years since diagnosis
0–4 weeks
5–11 weeks
12 weeks
Diagnostic interval:
0.00
0.25
0.50
0.75
1.00
0 1 2 3
0.00
0.25
0.50
0.75
1.00
0 1 2 3
Years since diagnosis
0–4 weeks
5–11 weeks
12 weeks
Diagnostic interval:
A B
Figure 2 Estimated survival according to the length of diagnostic
nterval analysed for colorectal cancer patients presenting with (A) alarm
symptoms of cancer or symptoms related to any serious illness and
(B) vague or ill-defined symptoms not directly related to cancer or any
other serious illness. The solid curves indicate 0–4 weeks; dashed curves
indicate 5–11 weeks; and dotted curves indicate X12 weeks from first
presentation of symptoms in primary care to diagnosis (the diagnostic
interval).
Table 3 Cumulative mortality (MR) and adjusted 3-year mortality ORs
for 268 incident colorectal cancer patients with GP involvement, according
to the length of the diagnostic interval (time from first presentation of
symptoms in primary care to diagnosis).
Diagnostic
interval
N MR Crude
OR (95% CI)
Adjusteda
OR (95% CI)
3-year mortality after diagnosis
(a) Patients presenting with alarm or any serious symptoms (N¼ 201)
0–4 weeks 75 48% 2.15 (1.14–4.08) 2.56 (1.29–5.05)
5–11 weeks 90 30% 1 (ref.) 1 (ref.)
X12 weeks 36 47% 2.09 (0.94–4.62) 2.04 (0.87–4.77)
(b) Patients presenting with vague symptoms (N¼ 67)
0–4 weeks 10 10% Comparison
not justified
Comparison
not justified
5–11 weeks 27 56% 1 (ref.) 1 (ref.)
X12 weeks 30 57% 0.96 (0.37–2.98) 0.71 (0.32–2.91)
1-year mortality after diagnosis
(a) Patients presenting with alarm or any serious symptoms (N¼ 201)
0–4 weeks 75 25% 1.70 (0.79–3.63) 2.09 (0.92–4.73)
5–11 weeks 90 17% 1 (ref.) 1 (ref.)
X12 weeks 36 31% 2.20 (0.89–5.41) 2.35 (0.88–6.26)
(b) Patients presenting with vague symptoms (N¼ 67)
0–4 weeks 10 10% Comparison
not justified
Comparison
not justified
5–11 weeks 27 37% 1 (ref.) 1 (ref.)
X12 weeks 30 23% 0.52 (0.16–1.64) 0.40 (0.11–1.48)
Abbreviations: GP¼ general practitioner; OR¼ odds ratio; CI, confidence interval.
aAdjusted for tumour site (colon/rectal), Charlson Comorbidity Index (0/1–2/X3),
age (18–59/60–74/X75), and sex. To address the possibility that emergency
admission was a confounder and not an intermediate step in the diagnostic pathway,
we additionally adjusted for emergency admission and repeated the analyses after
excluding patients with emergency admissions. In both subanalyses, we saw
comparable trends and no changes in estimates (data not shown).
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more homogeneous group with respect to confounders; and thus
obtained better internal validity. Furthermore, the analyses were
strengthened by allowing between-site variability in delay and
mortality and a nonmonotonic effect (Maguire et al, 1994); and by
addressing confounding by indication as discussed further below.
Limitations of the study
The limitations relating to the study design include possible
selection bias, information bias, and residual confounding.
First of all, 16.0% of the study base could not be included in the
final analyses because of nonparticipation of GPs. As seen on
Table 1, patients with nonparticipating GPs shared many of the
same clinical features as patients with uninvolved GPs, including
equal mortality rates. Thus, the GPs may not have been involved
in diagnosing cancer for a substantial part of these patients
(if patients, e.g., presented with emergency conditions and
bypassed their GP). Nevertheless, we cannot reject that some
GPs may have chosen not to participate, because they retro-
spectively believed they had caused undue delays in diagnosing
cancer. Given the observed convex and concave trends, it is
difficult to predict the direction of the bias due to selection.
Second, given the retrospectively collected data and the
comprehensive knowledge of GPs of their patients, we cannot
rule out differential misclassification regarding the length of the
diagnostic interval. Such misclassification would occur if, for
example, the GPs tended to understate the lengths of the diagnostic
intervals for patients who died shortly after diagnosis or were
diagnosed with advanced-stage cancers. If this were to be the case,
it would explain some of the excess mortality among patients with
short diagnostic intervals. To reduce information bias, GPs were
encouraged to consult their electronic medical records.
The consistent findings of higher mortality for short diagnostic
intervals among patients presenting with alarm symptom or any
serious symptoms – even after adjustment and exclusion of
patients with emergency admissions – could also be an indication
of residual confounding. Unknown confounding such as tumour
aggressiveness may have reversed the association, as patients with
rapidly growing tumours may exhibit more symptoms that may
raise appraisal and lead to shorter diagnostic intervals, but ever
worse outcomes. Although we were unable to account for the speed
of tumour growth and/or aggressive malignancies, we partly dealt
with confounding by appraisal by stratifying data according to the
symptom interpretation of the GP. This will be discussed further
below.
Finally, although it was an important tool in limiting the risk
of confounding, the stratification procedure and restriction also
reduced the power of the study. A larger study is needed to assess
the effect in patients presenting with vague symptoms.
COMPARISON WITH FINDINGS FROM OTHER
STUDIES
Most previous studies have examined the influence of total delay
(time from first symptom to treatment), total diagnostic delay
(time from first symptom to diagnosis), or provider delay (time
from first presentation of symptoms to treatment). Common for all
these studies is the mixing of patient, diagnostic, and/or treatment
delays. From a methodological point of view, it is particularly
tricky that both the prognostic factors and the premises for sorting
patients are likely to change during the pathway to treatment. The
best example is tumour stage, which is an important prognostic
factor at the time of diagnosis and surely a confounder of the
association between treatment delay and mortality. But, it does not
qualify as a confounder of the association between diagnostic delay
and mortality because it succeeds presentation. If we control for
this factor in studies of diagnostic delay, we create confounding.
Over the past three decades, the association between time to
diagnosis and mortality has been the subject of at least 14 studies
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Figure 3 Estimated 3-year mortality odds ratios (ORs) as a function of the diagnostic interval (time from first presentation of symptoms in primary care
until diagnosis) analysed for colorectal cancer patients presenting with (A) alarm symptoms of cancer or symptoms related to any serious illness and
(B) vague or ill-defined symptoms not directly related to cancer or any other serious illness. We adjusted for tumour site (colon/rectal), Charlson
Comorbidity Index (0/1–2/X3), age (18–59/60–74/X75), and sex. The solid curves indicate adjusted estimates with point-wise 95% confidence limits in
grey. The dashed curves indicate crude estimates. The grey spikes show the distribution of the diagnostic intervals on a squared scale. The grey horizontal
lines indicate the chosen reference point of 4 weeks (28 days).
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based on data from symptomatic colon and/or rectal cancer
patients (Irvin and Greaney, 1977; Polissar et al, 1981; Pescatori
et al, 1982; Hillon et al, 1985; Goh et al, 1987; Bako et al, 1988;
Porta et al, 1991; Auvinen, 1992; Ponz de Leon et al, 1992; Maguire
et al, 1994; Fernandez et al, 2002; Rupassara et al, 2006; Stapley
et al, 2006; Terhaar et al, 2010). The studies report either no
statistically significant association or the waiting time paradox.
The present study is pioneering in the sense that it challenges the
premises of former models. The finding of a U-shaped association
between the length of the diagnostic interval and mortality after
diagnosis of cancer provides evidence that previous studies may
not have represented reality very well; either because they did not
allow for a continuous, nonmonotonic effect (Hillon et al, 1985;
Porta et al, 1991; Rupassara et al, 2006) or because they introduced
bias by adjusting for intermediate variables such as tumour stage
(Polissar et al, 1981; Fernandez et al, 2002; Stapley et al, 2006;
Terhaar et al, 2010). This is the first study to address these issues
while at the same time controlling for confounding factors at first
presentation of symptoms in primary care.
Apart from contesting previous models, we believe that the
results may also challenge former reasoning. It has often been
speculated that the consistent findings of higher mortality for short
delays was caused by hidden confounders like the tumour’s speed
of growth and/or its ability to spread (Pescatori et al, 1982;
Auvinen, 1992; Rupassara et al, 2006). According to this theory,
aggressive tumours are associated with shorter delays because they
are easier to appraise (Neal, 2009). However, for this theory to hold
true, we would expect patients presenting with vague symptoms to
have an overall better survival than patients presenting with alarm
or any serious symptoms and to see similar trends for the two
groups. Apparently, this is not the case.
Underlying mechanisms and clinical implications
We believe that the contradictory findings of the waiting time
paradox mainly reflects confounding by indication, that is, a bias
stemming from the inherent difference in prognosis of patients
given different medical priority (Rothman, 2006). This mechanism
occurs if GPs, and subsequently diagnostic imaging centres and
endoscopic centres, as expected, give priority to seriously ill
patients who may have higher inherent mortality (the ‘sick-quick’
group), whereas being more reluctant to expedite patients with less
obvious symptoms of cancer (the ‘low risk– slow diagnosis’
group). This may even be supported by the fast-track guidelines.
The association of short diagnostic intervals and high mortality in
patients with alarm or serious symptoms and corresponding long
diagnostic intervals and low mortality in patients with vague
symptoms strongly supports the presence of this mechanism.
To conclude, most of the potential biases (from selection,
misclassification, confounding, and/or random error) will either
have influenced the results towards the null hypothesis or reversed
the association. Based on this observational study, we can only
speculate on the exact cause of the increased mortality with longer
diagnostic intervals. A biological explanation could be that the
exponential growth of the tumours predicates early diagnosis as a
crucial factor even for patients presenting with vague symptoms.
However, it should always be kept in mind that observational
studies do not test the hypothesis that expediting diagnosis
provides a mortality benefit. The diagnostic interval is a highly
complex variable reflecting tumour biology, patient behaviour, the
clinical pathway, and the functioning of the health-care system.
This study’s significance is that it provides some evidence against
the hypothesis that the diagnostic interval has no effect on
mortality and thus speaks against the tendency to downplay the
importance of the diagnostic interval.
CONCLUSION
On the basis of detailed primary-care data, this study shows the
waiting time paradox together with an increasing mortality
with longer diagnostic intervals in CRC patients presenting with
alarm or serious symptoms.
ACKNOWLEDGEMENTS
We thank the Department of Clinical Epidemiology for contribut-
ing data on comorbidity to the study. The three anonymous
journal referees made very sage points, and have improved the
paper. The study was supported by grants from the Danish Cancer
Society, the Novo Nordic Foundation, the Danish Graduate School
in Public Health Science, and Aarhus University. The sponsors
were not involved in any part of the study. The study was approved
by the Danish Data Protection Agency and the Danish National
Board of Health. According to the Committees on Biomedical
Research Ethics in the Central Denmark Region, the Act on a
Biomedical Research Ethics Committee System and the Processing
of Biomedical Research Projects does not apply to this project. All
authors had full access to data and take full responsibility for the
accuracy of the data analysis.
AUTHOR CONTRIBUTIONS
MLT was responsible for data acquisition from public and medical
databases, performed the statistical analyses, and wrote the paper.
She is the guarantor. MF supervised the statistical analyses and
designed programmes in Stata (version 11) (Statacorp LP, College
Station, TX, USA) for generating cubic splines with specific
reference values (centercsplines.ado) and estimates with standard
errors for linear combinations (calcest.ado) – both applied in
Figure 3. RPH designed the GP and patient questionnaires and was
responsible for this part of the data acquisition. PV and FO
initiated the study, and PV, MF, WH, and FO provided critical
revision of the intellectual content of the paper. All authors
contributed to the writing of and approved the final paper.
Conflict of interest
The authors declare no conflict of interest. FO is the chairman of
the Danish Cancer Society.
REFERENCES
Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM,
Parkin DM, Wardle J, Duffy SW, Cuzick J (2010) Once-only flexible
sigmoidoscopy screening in prevention of colorectal cancer: a
multicentre randomised controlled trial. Lancet 375: 1624 – 1633
Auvinen A (1992) Social class and colon cancer survival in Finland.
Cancer 70: 402 – 409
Bako G, Hill GB, Ferenczi L, Hanson J (1988) Factors influencing the survival
of patients with cancer of the colon or rectum. Chronic Dis Can 9: 101 – 104
Barrett J, Jiwa M, Rose P, Hamilton W (2006) Pathways to the diagnosis of
colorectal cancer: an observational study in three UK cities. Fam Pract
23: 15 – 19
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of
classifying prognostic comorbidity in longitudinal studies: development
and validation. J Chronic Dis 40: 373 – 383
Christiansen T (2002) Organization and financing of the Danish health care
system. Health Policy 59: 107 – 118
Time to diagnosis and mortality in CRC
ML Tørring et al
939
British Journal of Cancer (2011) 104(6), 934 – 940& 2011 Cancer Research UK
C
li
n
ic
a
l
S
tu
d
ie
s
Fernandez E, Porta M, Malats N, Belloc J, Gallen M (2002) Symptom-to-
diagnosis interval and survival in cancers of the digestive tract.
Dig Dis Sci 47: 2434 – 2440
Goh HS, Goh CR, Rauff A, Foong WC (1987) Clinico-pathological
prognostic factors of large bowel cancer in Singapore: a multivariate
analysis. Ann Acad Med Singapore 16: 437 – 440
Greenland S (1995) Dose-response and trend analysis in epidemiology:
alternatives to categorical analysis. Epidemiology 6: 356 – 365
Hansen RP (2008) Delay in the diagnosis of cancer. PhD thesis.
Ma˚nedsskrift for Praktisk Lægegerning: Kbh
Hansen RP, Olesen F, Sorensen HT, Sokolowski I, Sondergaard J (2008)
Socioeconomic patient characteristics predict delay in cancer diagnosis:
a Danish cohort study. BMC Health Serv Res 8: 49
Hewitson P, Glasziou P, Irwig L, Towler B, Watson E (2007) Screening for
colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane
Database Syst Rev, (1): CD001216
Hillon P, Faivre J, Milan C, Bedenne L, Piard F, Klepping C (1985) Cancers
of the rectum and colon in the Cote-d’Or department: treatment,
prognosis. Gastroenterol Clin Biol 9: 704 – 711
Irvin TT, Greaney MG (1977) Duration of symptoms and prognosis of
carcinoma of the colon and rectum. Surg Gynecol Obstet 144: 883 – 886
Iversen LH, Antonsen S, Laurberg S, Lautrup MD (2009) Therapeutic delay
reduces survival of rectal cancer but not of colonic cancer. Br J Surg 96:
1183 – 1189
Korsgaard M, Pedersen L, Sorensen HT, Laurberg S (2006) Reported
symptoms, diagnostic delay and stage of colorectal cancer: a population-
based study in Denmark. Colorectal Dis 8: 688 – 695
Maguire A, Porta M, Malats N, Gallen M, Pinol JL, Fernandez E (1994)
Cancer survival and the duration of symptoms. An analysis of
possible forms of the risk function. ISDS II Project Investigators..
Eur J Cancer 30A: 785 – 792
Mitchell E, Macdonald S, Campbell NC, Weller D, Macleod U (2008)
Influences on pre-hospital delay in the diagnosis of colorectal cancer: a
systematic review. Br J Cancer 98: 60 – 70
Neal RD (2009) Do diagnostic delays in cancer matter? Br J Cancer
101(Suppl 2): S9 – S12
NORDCAN (2009) Cancer stat fact sheets: Denmark – colorectal cancer
Olesen F, Hansen RP, Vedsted P (2009) Delay in diagnosis: the experience
in Denmark. Br J Cancer 101(Suppl 2): S5 – S8
Pescatori M, Maria G, Beltrani B, Mattana C (1982) Site, emergency, and
duration of symptoms in the prognosis of colorectal cancer. Dis Colon
Rectum 25: 33 – 40
Polissar L, Sim D, Francis A (1981) Survival of colorectal cancer patients in
relation to duration of symptoms and other prognostic factors. Dis Colon
Rectum 24: 364 – 369
Ponz de Leon M, Sant M, Micheli A, Sacchetti C, Di Gregorio C, Fante R,
Zanghieri G, Melotti G, Gatta G (1992) Clinical and pathologic prognostic
indicators in colorectal cancer. A population-based study. Cancer 69:
626 – 635
Porta M, Gallen M, Malats N, Planas J (1991) Influence of ‘diagnostic
delay’ upon cancer survival: an analysis of five tumour sites. J Epidemiol
Community Health 45: 225 – 230
Ramos M, Esteva M, Cabeza E, Campillo C, Llobera J, Aguilo A (2007)
Relationship of diagnostic and therapeutic delay with survival in
colorectal cancer: a review. Eur J Cancer 43: 2467 – 2478
Rothman KJ (2006) Epidemiology: An Introduction. Oxford University
Press: New York, NY
Rupassara KS, Ponnusamy S, Withanage N, Milewski PJ (2006) A paradox
explained? Patients with delayed diagnosis of symptomatic colorectal
cancer have good prognosis. Colorectal Dis 8: 423 – 429
Sørensen HT ed. (2009) Use of Medical Databases in Clinical Epidemiology.
Department of Clinical Epidemiology, Aarhus University Hospital:
Aarhus
Stapley S, Peters TJ, Sharp D, Hamilton W (2006) The mortality of
colorectal cancer in relation to the initial symptom at presentation to
primary care and to the duration of symptoms: a cohort study using
medical records. Br J Cancer 95: 1321 – 1325
Terhaar JS, Oort F, van dH, Coupe V, Craanen M, Meijer G, Morsink L,
Visser O, van Wanrooij R, Mulder C (2010) Does delay in diagnosing
colorectal cancer in symptomatic patients affect tumor stage
and survival? A population-based observational study. BMC Cancer
10: 332
This work is licensed under the Creative Commons
Attribution-NonCommercial-Share Alike 3.0 Unported
License. To view a copy of this license, visit http://creativecommons.
org/licenses/by-nc-sa/3.0/
Time to diagnosis and mortality in CRC
ML Tørring et al
940
British Journal of Cancer (2011) 104(6), 934 – 940 & 2011 Cancer Research UK
C
lin
ic
a
l
S
tu
d
ie
s
